HDAC-IN-35

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

HDAC-IN-35 

HDAC-IN-35 (Compound 14) 是一个有效的、选择性的 HDAC 和 VEGFR-2 抑制剂，对 HDAC6 和 VEGFR-2 的 IC50 值分别为0.166和13.2 µM。

HDAC-IN-35

HDAC-IN-35 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC50 values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively[1].

IC50 & Target

HDAC6

0.166 μM (IC50)

HDAC8

1.99 μM (IC50)

HDAC1

7.23 μM (IC50)

VEGFR2

13.2 μM (IC50)

体外研究
(In Vitro)

HDAC-IN-35 (Compound 14) (0-10 µM, 48 h) shows anticancer effects in different cancer cells[1].
HDAC-IN-35 (0-10 µM, 48 h) exhibits potent anti-angiogenic activity with a GI>50 (50% growth inhibition) value of 1.0 μM on human endothelial progenitor cells (EPCs) through a VEGFR-2-dependent pathway, without obvious systemic toxicity[1].
HDAC-IN-35 exhibits moderate VEGFR-2 inhibitory activities and displays the anticancer effects by inhibiting the enzymatic activity of HDAC[1].
HDAC-IN-35 (0-10 µM, 24 h) concentration-dependently impedes the capillary-like tube formation in human EPCs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: A549, PC-3, and SK-Hep-1
Concentration: 0-10 µM
Incubation Time: 48 h
Result: Showed anticancer effects with IC50 values of 3.4, 1.9 and 3.2 µM against A549, PC-3, and SK-Hep-1 cells.

Western Blot Analysis[1]

Cell Line: A549, PC-3, and SK-Hep-1, and human EPCs
Concentration: 0, 5, and 10 µM
Incubation Time: 24 h
Result: Increased the amount of acetylated α-tubulin and histone H3 in a concentration-dependent manner in cancer cells. Induced mild inhibition of the phosphorylation of VEGFR-2 in human EPCs.

分子量

399.75

Formula

C17H13ClF3N3O3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Szu Lee, et al. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. Bioorg Med Chem. 2021 Nov 15;50:116454.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复